While there have been recent breakthroughs in targeting KRAS G12C in NSCLC and KRAS G12D in pancreatic cancer, there is yet to be a KRAS G12V-specific compound, and there is an unmet clinical need for strategies to target this tumor subtype. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.